Fig. 2
The one-way sensitivity analyses of sacituzumab govitecan compared to chemotherapy in China. (Note: PD, progressive disease; PFS, progression-free survival; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year)
Fig. 2 | Cost Effectiveness and Resource Allocation